An observational study in Pancreas (Including SPK) Transplantation, Pancreas Diseases and Pancreas Transplant Rejection, sponsored by Paragonix Technologies. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Paragonix Technologies · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to collect real-world clinical performance data to assess the clinical outcomes of patients receiving pancreas transplants using donor pancreata transported via the PancreasPak system. These results will be compared to standard of care outcomes, as well as other preservation methods.
GUARDIAN-PANCREAS is a post-market, observational registry of adult transplant recipient patients whose donor pancreas was preserved and transported within the PancreasPak. The data is being collected retrospectively from medical records of patients already transplanted before the initiation of the registry and any new patients who meet the eligibility criteria.
About 1000 subjects meeting the study inclusion and exclusion criteria will be enrolled into the study at about 15 clinical sites.
Candidates that fit the eligibility criteria and have had their donor pancreas transported with a Paragonix product or a standard of care method can be enrolled. The baseline characteristics and outcomes of the two groups will be compared.
184 studies on the registry are indexed under Pancreatic Diseases; 61 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 363 across 76 observational studies indexed under Pancreatic Diseases.
Browse Pancreatic Diseases studies →Paragonix Technologies is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients who have received a pancreas transplant at centers that use the PancreasPak device.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients whose donor pancreas was transported with the PancreasPak device.
Device: PancreasPak
Patients whose donor pancreas was transported with a method other than the PancreasPak device.
The PancreasPak Donor Preservation System is a FDA cleared and CE-marked medical device intended to be used for the static hypothermic preservation of donor pancreata during transportation and eventual transplantation using cold preservation solutions indicated for use in donor pancreata transplantation. The intended organ preservation time for the PancreasPak system is up to 21 hours.
Graft dysfunction
The percentage of subjects in each cohort who experience graft dysfunction post-transplant.
Time frame: Post-transplant through 1 year post-transplant
Pancreatitis
The percentage of subjects in each cohort who experience pancreatitis post-transplant.
Time frame: Post-transplant through 1 year post-transplant
Primary Non-Function
The percentage of subjects in each cohort who primary non-function post transplantation.
Time frame: Post-transplant through 7 days post-transplant
Length of Hospital Stay
How many days the patients stays in the hospital post-transplant.
Time frame: 1 year
Surgical Complications
The percentage of subjects in each cohort who experience surgical complications.
Time frame: Post-transplant through 1 year post-transplant
Insulin Dependence
The percentage of subjects in each cohort who experience insulin dependence post-transplant.
Time frame: Post-transplant through 1 year post-transplant
Graft Failure
The percentage of subjects in each cohort who develop graft failure post-transplant.
Time frame: Post-transplant through 1 year post
Survival
The percentage of subjects in each cohort who survive through 1 year post-transplant.
Time frame: Post-transplant through 1 year post
Length of ICU Stay
How many days the patient stayed in the ICU post-transplant.
Time frame: 1 year
Interventions for Anastomotic Complications
The percentage of subjects in each cohort who required interventions due to anastomotic complications.
Time frame: Post-transplant through 1 year post-transplant
Intervention for Vascular Complications
The percentage of subjects in each cohort who required interventions due to vascular complications.
Time frame: Post-transplant through 1 year-post transplant
Medications
The percentage of subjects in each cohort who required the use of various medications.
Time frame: Post-transplant through 1 year post-transplant
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jun 2031, 53 months later.
Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jan 2027, on Sep 28, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Paragonix Technologies